Figure 5. Axl inhibition promotes CD103⁺ DC accumulation and activation.

C57BL/6 mice (3 per group) bearing 10-day-established ID8 tumors were treated with control vehicle or R428 for 5 days and tumor-infiltrating cDCs were analyzed by FACS. (A) Representative FACS plots for CD103 versus CD11b within CD11c⁺ MHCII⁺ cDC gate, and percentage (within CD11c⁺ MHCII⁺ cells) and absolute number of CD103⁺ CD11c⁺ MHCII⁺ cDCs. (B) Representative FACS plots for CD86 versus CD40 within CD11b⁺ or CD103⁺ CD11c⁺ MHCII⁺ gate and percentage of CD86⁺ CD40⁺ within CD11b⁺ or CD103⁺ CD11c⁺ MHCII⁺ cDCs. (C) Representative FACS plots for CD11c versus IL-12p40 within CD11b⁺ or CD103⁺ CD11c⁺ MHCII⁺ gate and percentage of IL-12p40⁺ within CD11b⁺ or CD103⁺ CD11c⁺ MHCII⁺ cDCs. Data are representative of two independent experiments, *p < 0.05, **p < 0.01, two-tailed student t test.